The company reported a profit before tax of Rs 77.72 crore in Q1 FY27 compared with a pre-tax loss of Rs 36.66 crore in Q1 FY26. It also recorded exceptional gains of Rs 97.34 crore during the quarter.

Aditi Panandikar, managing director, Indoco Remedies, said, “The first quarter of the financial year 2026-27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient domestic formulation business, while our international formulations and API businesses continued to make steady progress.”

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company's turnover is $175 million with human capital of over 6,000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

Shares of Indoco Remedies fell 5.89% to Rs 233.15 on the BSE.